At the MassGeneral Institute for Neurodegenerative Disease (MIND), more than 200 scientists, physicians and technical staff are unified behind one goal: to eliminate the devastating effects of neurodegenerative disease.

Plaques

Alzheimer’s Disease

“Every new Alzheimer’s gene we identify provides clues to the cause of this dreadful disease. Knowledge gained from Alzheimer’s-associated genetic defects should greatly accelerate our efforts to treat and prevent Alzheimer’s disease.”
Rudy Tanzi, PhD
Genetics and Aging Research Unit

 

ALS substantia nigra

Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's disease)

“Fifteen years ago, there was no treatment for ALS and not much to try. Now, research discoveries are so numerous that we have to prioritize the most promising ideas.”
Merit Cudkowicz, MD
Director, Mass General Neurology Clinical Trials Unit

 

H3TG, genetics

Huntington’s Disease

“Large amounts of creatine have to be ingested in order for therapeutic levels to reach the brain, so safety was a big concern.  We were amazed to see that a blood biomarker that detects brain degeneration was normalized, and brain imaging showed a slowing of brain shrinkage.”
Steven Hersch, MD, PhD
Huntington's Disease Clinical Unit

 

Neurons with plaques

Parkinson’s Disease

“We think that there are important clues about the origin and progression of PD [in data that suggests PD, when it occurs, is more aggressive in women]. Ultimately, we want to determine if PD therapies could be more effective with gender-specific tailoring.”
Anne B. Young, MD, PhD
Director, MassGeneral Institute for Neurodegenerative Disease